- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05741619
Long-term Follow up of Patient With Anti-GABAbr Antibodies Associated-encephalitis. (SALTEA GABAbr)
First described in 2010, GABA-B-receptor antibodies-associated encephalitis is a disease with a severe vital and functional prognosis. Indeed, functional status is mostly altered by encephalitis and it induced consequences while vital status is mostly engaged by cancer very often associated in the course of the disease, mostly small-cell lung cancer (SCLC).
While knowledge is growing on clinical features at each stage of the disease, long-term outcome data is still lacking even if known to be pejorative.
In this study, we aimed to describe long-term follow up of all patients who were diagnosed a GABAb-receptor antibodies-associated encephalitis in the French Paraneoplastic Neurological Syndrome Reference Center until now.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Lyon, France, 69677
- Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites autoimmunes
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- encephalitis tested positive to GABAbr-antibodies after the examination of CSF samples tested for autoimmune encephalitis at the French Paraneoplastic Neurological Syndrome Reference Center from January 2011 to January 2022.
Exclusion Criteria:
- tested positive to another onconeural antibody.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Anti-GABABr encephalitis
This is a non-interventional study involving clinical data.
This data are information of medical follow up on patient like diagnosis, symptoms, biological results, cancer, treatments.
|
Autonomy, physical examination, behavioural disorders
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified-Rankin scale (mRS)
Time Frame: At 60 month (after the beginning of the disease)
|
Modified-Rankin scale (mRS) ranked from 0 (full autonomy) to 6 (death)
|
At 60 month (after the beginning of the disease)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 897 (Other Grant/Funding Number: M.S.I. Foundation)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autoimmune Encephalitis
-
Hoffmann-La RocheChugai Pharmaceutical Co.RecruitingNMDAR Autoimmune Encephalitis | LGI1 Autoimmune EncephalitisUnited States, Korea, Republic of, China, Japan, Czechia, Italy, Poland, Austria, Brazil, Argentina, Netherlands, Taiwan, Denmark, France, Ghana
-
Seoul National University HospitalWithdrawnAutoimmune EncephalopathyKorea, Republic of
-
Medical University of ViennaCompletedPost Other Specified Vaccination EncephalitisAustria
-
Seoul National University HospitalCompletedEncephalitis
-
Hospices Civils de LyonCompletedAutoimmune EncephalitisFrance
-
Hospices Civils de LyonCompleted
-
University of BernNovartis; University Hospital Inselspital, Berne; Schweizerische Multiple Sklerose... and other collaboratorsRecruitingMultiple Sclerosis | Optic Neuritis | Neuromyelitis Optica Spectrum Disorder | CNS Sarcoidosis | CNS Vasculitis | Transverse Myelitis | Rasmussen Encephalitis | Acute Disseminated Encephalomyelitis | Anti-NMDAR Encephalitis | Anti-GAD65 Associated Autoimmune Encephalitis | Anti-AMPAR-1/2 Associated Autoimmune... and other conditionsSwitzerland
-
University Hospital, Strasbourg, FranceCompletedAcute Autoimmune EncephalitisFrance
-
Hospices Civils de LyonUnknownAutoimmune Encephalitis | Anti NMDA Receptor Encephalitis | Herpetic EncephalitisFrance
-
Hospices Civils de LyonRecruitingAutoimmune Encephalitis Associated With Anti-CAPR2 AntibodiesFrance
Clinical Trials on Long-term outcome
-
Hospices Civils de LyonCompletedCerebellar HypoplasiaFrance
-
Azienda Ospedaliera Cardinale G. PanicoUnknown
-
University Hospital, Basel, SwitzerlandCompleted
-
Ukraine Association of BiobankActive, not recruitingDiabete Type 2 | Mesenchymal Stem CellUkraine
-
Helsinki University Central HospitalCompleted
-
Mental Health Services in the Capital Region, DenmarkUniversity of Copenhagen; Copenhagen Trial Unit, Center for Clinical Intervention...Completed
-
Sun Yat-sen UniversityUnknownMultifocal Contact LensesChina
-
Haukeland University HospitalOslo University Hospital; University Hospital of North Norway; Helse Stavanger... and other collaboratorsRecruitingNervous System Diseases | Neurodegenerative Diseases | Motor Neuron Disease | Amyotrophic Lateral Sclerosis | Spinal Cord Diseases | TDP-43 ProteinopathiesNorway
-
University of BernCompletedDental Implants | PeriimplantitisSwitzerland
-
RenJi HospitalZhujiang Hospital; Clinical Research Institute, Shanghai Jiao Tong University...Not yet recruitingTraumatic Brain Injury | Subdural Effusion | Decompressive CraniectomyChina